Phenoxybenzamine + Doxazosin
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pheochromocytoma
Conditions
Pheochromocytoma
Trial Timeline
Dec 1, 2011 → Jan 1, 2018
NCT ID
NCT01379898About Phenoxybenzamine + Doxazosin
Phenoxybenzamine + Doxazosin is a approved stage product being developed by Atrium Therapeutics for Pheochromocytoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01379898. Target conditions include Pheochromocytoma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01379898 | Approved | Completed |
Competing Products
4 competing products in Pheochromocytoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anlotinib and Benmelstobart | Sun Pharmaceutical | Phase 2 | 52 |
| Belzutifan | Merck | Phase 2 | 52 |
| Axitinib | Pfizer | Phase 2 | 51 |
| ONC206 + ONC206: Dose 1 + ONC206: Dose 2 | Jazz Pharmaceuticals | Phase 2 | 49 |